Latest article
Fierce Pharma Asia—AstraZeneca-Junshi PD-1 deal; Takeda’s $1.2B diabetes selloff, Ovid epilepsy collab pullout
In a strangely structured deal, AstraZeneca has nationwide licensed Junshi Biosciences' PD-1 inhibitor for only one indication in China. Takeda continued to sell...
Go Low-Carb for Sort 2 Diabetes Remission?
Overall, the Brinkworth team found that low-carb diets were successful after six months: people on these...
